Citius Oncology, Inc. (CTOR)

In August 2025, Citius Oncology reported its fiscal Q3 2025 results, including a net loss of $5.4 million, and announced successful fundraising of $21.5 million to support the LYMPHIR launch, which was on track for Q4 2025. In September 2025, the company completed a $9 million registered direct offering and concurrent private placement. In October 2025, Citius Oncology inked a distribution services agreement with McKesson for LYMPHIR. In December 2025, Citius Oncology announced the closing of an $18 million concurrent registered direct offering and private placement and reported its fiscal year 2025 financial results with an EPS of ($0.06), meeting consensus estimates, and LYMPHIR was commercially launched in the U.S. In January 2026, shareholder consent was approved for the issuance of shares upon the exercise of warrants tied to the December 2025 and prior offerings, and a shareholder investigation by Purcell & Lefkowitz LLP was announced. Citius Oncology's stock has lost approximately 50% since September 30, 2025, primarily due to significant shareholder dilution from multiple equity financing rounds.

Information specifically detailing the demand seasonality for Citius Oncology, Inc.'s products and services is not available in the provided search results. Demand for LYMPHIR is likely driven by patient diagnoses and treatment protocols rather than typical seasonal consumer patterns. The company's focus on a niche market with an unmet medical need suggests a more consistent demand tied to disease prevalence rather than seasonal fluctuations.

Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. It operates in the Biomedical/Gene industry, specifically Pharmaceutical Products. Founded on March 1, 2021, and headquartered in Cranford, New Jersey, it is a majority-owned publicly-traded subsidiary of Citius Pharmaceuticals, Inc. The company's primary product, LYMPHIR, is FDA-approved for relapsed or refractory cutaneous T-cell lymphoma (CTCL) in adults after one prior systemic therapy and was launched in the U.S. in December 2025. Management estimates the initial market for LYMPHIR exceeds $400 million.

Citius Oncology, Inc. is headquartered in Cranford, New Jersey, USA. While its primary market focus for LYMPHIR is the U.S., the company has also begun laying the groundwork for international access, including distribution service agreements with leading global providers and establishing key distribution partners spanning 19 markets in Southern Europe and the Middle East via Named Patient Programs. The company has also executed service agreements with three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR to healthcare organizations.

The FDA approval and commercial launch of LYMPHIR are positive events for Citius Oncology's brand reputation. Analyst ratings suggest a mixed but generally cautious outlook, with a consensus rating of "Hold". Significant shareholder dilution and stock price decline could negatively impact investor confidence. The shareholder investigation could potentially harm the company's reputation. MarketBeat ranked Citius Oncology higher than 42% of companies evaluated and 640th out of 877 stocks in the medical sector, indicating a moderate position within its industry.

Citius Oncology, Inc. has 18 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, holding a total of 8,358,659 shares, including Armistice Capital, Llc, Vanguard Group Inc, and Geode Capital Management, Llc. Citius Pharmaceuticals, Inc. is a significant owner, holding approximately 78% of Citius Oncology.